key: cord-0788565-7uurvww8 authors: Abohamr, Samah I; Abdulrahim, Abubaker E; Hussein, Nada M; Elsheikh, Eman; ALhindi, Duaa A; Saadeddin, Hiba M; Abazid, Rami M title: Multimodality Imaging in COVID19 Patient with Large Mobile RV Thrombus Protruding into the Pulmonary Trunk with Bilateral Pulmonary Embolism date: 2021-09-09 journal: J Cardiol Cases DOI: 10.1016/j.jccase.2021.08.008 sha: f9606387aead318e7824ccc4a44bb3ea153315be doc_id: 788565 cord_uid: 7uurvww8 Inflammation related to coronavirus disease (COVID)-19 can promote a pro-thrombotic process and subsequent thrombosis. We report a confirmed COVID-19 case in a 51-year-old patient who presented with chest pain and severe hypoxemia. Although the right heart chambers are unusual locations for a thrombus, an echocardiogram demonstrated a large mobile right ventricular thrombus protruding into the right ventricle outflow tract. A computed tomography angiogram and cardiac magnetic resonance image showed the extension of the thrombus into the pulmonary trunk. A continuous intravenous unfractionated heparin infusion resulted in a dramatic clinical and echocardiographic improvement. Inflammation related to coronavirus disease (COVID)-19 can promote a pro-thrombotic process and subsequent thrombosis. We report a confirmed COVID-19 case in a 51-year-old patient who presented with chest pain and severe hypoxemia. Although the right heart chambers are unusual locations for a thrombus, an echocardiogram demonstrated a large mobile right ventricular thrombus protruding into the right ventricle outflow tract. A computed tomography angiogram and cardiac magnetic resonance image showed the extension of the thrombus into the pulmonary trunk. A continuous intravenous unfractionated heparin infusion resulted in a dramatic clinical and echocardiographic improvement.  With COVID-19 infection, the thrombus phenomenon is becoming more common.  Since thromboembolic complications are common in patients with severe COVID-19 who need intensive care unit care, heparin infusion is recommended for patients who are unlikely to need procedures.  Multimodality imaging can be useful in determining the diagnosis, prognosis, and treatment plan. Thrombosis related to coronavirus disease (COVID)-19 has been frequently reported during the disease's active phases and recovery period and can be associated with higher morbidity and mortality. The most reported thromboembolic phenomena associated with COVID-19 are acute coronary syndrome, pulmonary embolism (PE), deep vein thrombosis, superior mesenteric artery thrombosis, renal infarct, and acute ischemic stroke [1, 2] . The hypercoagulability that accompanies COVID-19 is caused by systemic inflammation, endothelial damage, immobility, and hypoxia [3] . A right ventricular (RV) thrombus is uncommon. It is typically observed with a coinciding pulmonary embolism and can worsen the prognosis [4] . We present a case report with a large mobile RV thrombus protruding into the RV outflow tract (RVOT) in a confirmed COVID-19 case. A 51-year-old man with no significant previous medical history presented with a fever (38.8 o C), diarrhea, shortness of breath, and pleuritic chest pain for four days before admission. On physical examination, his blood pressure was 126/77 mmHg, heart rate was 100 beats/min, oxygen saturation was 88% on room air, and respiratory rate was 25/min. His cardiovascular examination was remarkable for tachycardia and a loud second heart sound. His laboratory tests revealed an elevated troponin level of 0.528 ng/mL (normal range 0-0.05 ng/mL) with a high pro-B-type natriuretic peptide of 3936 pg/mL (normal range 0-125 pg/mL), a D-dimer level of 9.08 mg/L (normal range 0-0.5 mg/L), and a lactate dehydrogenase of 301.32 U/L (normal range 85-227 U/L). The initial electrocardiogram showed sinus tachycardia with an S1Q3T3 sign (Fig. 1) and left lower lobe consolidation, likely lung infarction (Fig. 3, Online, Figs 1-3, Movie 3 , and Movie 6). Besides PE management, the protocol for patients with confirmed COVID-19 is using favipiravir: 1800 mg/dose twice a day on the first day followed by 800 mg/dose twice a day for 7-10 days. Given his hemodynamic profile, the cardiology and cardiothoracic surgery team discussed various therapeutic approaches, such as systemic thrombolysis and surgical embolectomy [5] . However, as a COVID-19 outbreak was a major concern, the management plan was to commence intravenous unfractionated heparin while awaiting coagulation profile results and excluding any sources of embolization. Regardless, thrombolytic therapy would be considered if the hemodynamic profile deteriorated. A lower limb duplex revealed no evidence of deep vein thrombosis. A coagulation profile showed normal prothrombin time, partial thromboplastin time, protein C, and protein S levels, and negative anti-cardiolipin IgG and B2 glycoprotein 1 (IgG) antibodies. The patient's vital signs showed gradual improvement. Moreover, a serial TTE confirmed regression of the thrombus. As the pre-discharge TTE showed a normal RV function with no remnant clot, the patient was discharged home on a therapeutic dose of warfarin. We reported on a COVID-19 patient presenting with a submissive PE as an extension of a large RV thrombus. In this case report, we used multimodal imaging to confirm the diagnosis. There are multiple mechanisms of thrombosis in COVID-19, such as increased blood viscosity, hypoxia-inducible transcription factor-dependent signaling cascade [6] , hypoxia, direct infection symptoms, and disseminated intravascular coagulation [7] . Similar to this case, Athappan et al. and Kaplan et al. reported right heart mural thrombi in COVID-19 patients [8, 9] . Evolving literature has demonstrated the importance of multimodal imaging, including echocardiography, computed tomographic pulmonary angiography, and cardiac magnetic resonance imaging in a diagnosis and management plan [1] [2] [3] . The treatment choices for RV thrombosis include anticoagulants, thrombolytic therapy, and surgical thrombectomy. Studies suggest a survival benefit with either thrombolysis or surgery [10] , while active thrombolytic therapy has been reported in unstable COVID-19 patients complicated with right heart thrombi [10] . The patient's stable presentation led us to begin with a conservative approach. Despite the acuity of his illness, his rapid improvement within 24 hours convinced us to postpone thrombolysis or thrombectomy. We do not yet have adequate answers to questions emerging from the complexities and management problems of severe COVID-19 cases, as the global scientific community is still studying COVID-19 complications. However, in patients with serious COVID-19 requiring intensive care unit treatment, thromboembolic complications are common, and heparin infusion may be recommended for patients who are unlikely to require procedures. We have detailed a case of a critical RV thrombus in a COVID-19 patient. COVID-19 likely contributes to a higher risk of developing thromboembolic disorders. Clinically diagnosing and treating thromboembolic consequences in this condition requires a high level of attentiveness. Finally, multimodal imaging plays a key role in the diagnosis, prognosis, and treatment approach. The authors declare that there is no conflict of interest. Description and proposed management of the acute COVID-19 cardiovascular syndrome Treatment of right heart thrombi associated with acute pulmonary embolism COVID-19 and cardiovascular disease Right heart thrombi in pulmonary embolism The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC) COVID-19-driven endothelial damage: complement, HIF-1, and ABL2 are potential pathways of damage and targets for cure Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia Comparative efficacy of different modalities for treatment of right heart thrombi in transit: a pooled analysis resulting in bilateral pulmonary emboli and a right ventricular thrombus: association or causation? A case report Multisystem imaging manifestations of COVID